BOMES: a promising combination chemotherapy in the treatment of CNS lymphoma (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

BOMES: a promising combination chemotherapy in the treatment of CNS lymphoma (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A500 1994. Unique Identifier : AIDSLINE ICDB/94600496
Cheng AL; Yeh KH; Chen BR; Uen WC; Tien HF; Wang CH; Chen YC; Cancer Res. Center, Natl. Taiwan Univ. Coll. of Medicine, Taipei,; Taiwan

Abstract: Although with occasionally excellent results with corticosteroid treatment, the response of CNS lymphoma to systemic chemotherapy remains unsatisfactory. This is presumably partly due to the blood-brain barrier (BBB). To cope with this, we designed a protocol which, in addition to high-dose corticosteroids, consisted of drugs that cross BBB. The regimen included BCNU 65 mg/m2 iv D1,2; vincristine 2 mg iv D1,8; etoposide 50 mg/m2 iv D1-5; methylprednisolone 200 mg/day iv D1-5; and methotrexate 1.5 gm/m2 iv D15, followed by leucovorin rescue. The course was repeated every 3 wk. All patients were anti-HIV(-), and 5 patients had systemic lymphoma involvement. The histology type included 8 diffuse large cell, 1 small noncleaved, and 1 primary meningeal lymphomas. Chemotherapy and cranial irradiation has been previously given in 3 and 4 patients, respectively. Myelosuppression was the limiting toxicity, with ECOG Gr3-4 leukopenia developed in 50% of 32 courses given and Gr3 infection in 2 patients. One hepatitis B carrier died of fulminant hepatitis. CR and PR were seen in 6 and 3 patients, respectively; with a response rate of 90% (56%-99%, 95% CI). The remission duration of complete responders was 1+, 2, 3+, 7, 20+, 30+ mo, respectively. We suggest that BOMES is an effective regimen in the treatment of CNS lymphoma. Further study in a larger group of patients is indicated.

Keywords: Antineoplastic Agents, Combined/ADVERSE EFFECTS/PHARMACOKINETICS/ *THERAPEUTIC USE Blood-Brain Barrier/DRUG EFFECTS/PHYSIOLOGY Brain Neoplasms/BLOOD/*DRUG THERAPY Carmustine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS Dose-Response Relationship, Drug Drug Administration Schedule Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS Human Leucovorin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS Methotrexate/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS Methylprednisolone/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS Vincristine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS ABSTRACT
941030
M94A0892

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .